Potent and selective p38 MAP kinase inhibitor (IC50 = 44 nM for p38α). Displays > 220-fold selectivity over ERK, JNK1 and other kinases; ~ 3-fold more selective than SB 203580 (Cat. Nos. 1202 and 1402). Reduces inflammatory cytokine production and is neuroprotective following oral administration in vivo.
Sold for research purposes under agreement from GlaxoSmithKline
|Storage||Desiccate at +4°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
|DMSO||3.68||10mM with gentle warming|
Preparing Stock Solutions
The following data is based on the product molecular weight 368.41. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2.71 mL||13.57 mL||27.14 mL|
|5 mM||0.54 mL||2.71 mL||5.43 mL|
|10 mM||0.27 mL||1.36 mL||2.71 mL|
|50 mM||0.05 mL||0.27 mL||0.54 mL|
References are publications that support the products' biological activity.
Barone et al (2001) SB 239063, a second-generation p38 mitogen-activated protein kinase inhibitor, reduces brain injury and neurological deficits in cerebral focal ischemia. J.Pharmacol.Exp.Ther. 296 312 PMID: 11160612
Legos et al (2002) The selective p38 inhibitor SB-239063 protects primary neurons from mild to moderate excitotoxic injury. Eur.J.Pharmacol. 447 37 PMID: 12106800
Underwood et al (2000) SB 239063, a potent p38 MAP kinase inhibitor, reduces inflammatory cytokine production, airways eosinophil infiltration, and persistence. J.Pharmacol.Exp.Ther. 293 281 PMID: 10734180
If you know of a relevant reference for SB 239063, please let us know.
View Related Products by Product Action
Keywords: SB 239063, supplier, Potent, selective, p38, MAP, kinases, inhibitors, inhibits, orally, active, MAPK, Signaling, Signalling, Mitogen-Activated, Protein, SB239063, GlaxoSmithKline, GSK, p38, p38, Tocris Bioscience
4 Citations for SB 239063
Citations are publications that use Tocris products. Selected citations for SB 239063 include:
Agusti et al (2014) Rats with minimal hepatic encephalopathy due to portacaval shunt show differential increase of translocator protein (18 kDa) binding in different brain areas, which is not affected by chronic MAP-kinase p38 inhibition. J Mol Neurosci 29 955 PMID: 24307181
Potapova et al (2013) Caspases and p38 MAPK regulate endothelial cell adhesiveness for mesenchymal stem cells. Metab Brain Dis 8 e73929 PMID: 24069252
Ferreira et al (2011) Neuropeptide Y inhibits interleukin-1β-induced phagocytosis by microglial cells. PLoS One 8 169 PMID: 22136135
He and Aizenman (2010) ERK signaling leads to mitochondrial dysfunction in extracellular zinc-induced neurotoxicity. J Neurochem 114 452 PMID: 20412391
Do you know of a great paper that uses SB 239063 from Tocris? If so please let us know.
SB 239063 Reviews
Average Rating:(Based on 0 Reviews)
Literature in this Area
MAPK Signaling Scientific Review
MAP kinase signaling is integral to the regulation of numerous cellular processes such as proliferation and differentiation, and as a result is an important focus of cancer and immunology research. Updated for 2016, this review discusses the regulation of the MAPK pathway and properties of MAPK cascades. Compounds available from Tocris are listed.